A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma

Cancer

Volumn 80, Issue 2, 1997, Pages 317-333

  Frost, Jami D ^a,k   Hank, Jacquelyn A ^a   Reaman, Gregory H ^b   Frierdich, Sharon ^a   Seeger, Robert C ^c   Gan, Jacek ^a   Anderson, Peter M ^d   Ettinger, Lawrence J ^e   Cairo, Mitchell S ^f   Blazar, Bruce R ^g   Krailo, Mark D ^h   Matthay, Katherine K ⁱ   Reisfeld, Ralph A ^j   Sondel, Paul M ^a,h  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d MAYO CLINIC   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j SCRIPPS RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF NEW MEXICO   (United States)

more..

Author keywords

Anti GD2 antibody; Interleukin 2; Neuroblastoma; Pediatrics; Phase I trial

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14.G2A; UNCLASSIFIED DRUG;

ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DIAGNOSTIC APPROACH ROUTE; DRUG TOLERABILITY; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOTHERAPY; MALE; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; GANGLIOSIDES; HUMANS; INTERLEUKIN-2; MALE; MICE; NEOPLASM PROTEINS; NEUROBLASTOMA; RECOMBINANT PROTEINS; REMISSION INDUCTION;

EID: 0030929898     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W     Document Type: Article

References (47)

1. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995; 75:2186-95.
2. Reynolds CP, Seeger RC, Vo DD, Black AT, Wells J, Ugelstad J. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986;46:5882-6.
3. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary MC, Harris RE, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. J Clin Oncol 1994; 12:2382-9.
4. Rosenberg SA, Yang JC, Topalian SL, Schwartentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin-2. J Am Med Assoc 1994;271:907-13.
5. Parkinson DR. IL-2 in cancer therapy. Semin Oncol 1988;15:10-26.
6. Sondel PM, Hank JA, Kohler PC, Sosman JA, Weil-Hillman G, Fisch P, et al. The cellular immunotherapy of cancer: current and potential uses of IL-2. Crit Rev Oncol Hematol 1989;9:125-47.
7. Hank JA, Kohler PC, Weil-Hillman GW, Rosenthal N. Moore KH, Storer B, et al. In vivo induction of the lymphokineactivated killer phenomenon: IL-2 dependent human nonmajor histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant IL-2. Cancer Res 1988;48:1965-71.
8. Sondel PM, Hank JA, Kohler PC, Chen BP, Minkoff DZ, Molenda JA, et al. Destruction of autologous human lymphocytes by IL-2 activated cytotoxic cells. J Immunol 1986;137:502-11.
9. Damle NK, Doyle LV, Bender JR, Bradley EC. IL-2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 1987;138:1779-85.
10. Ettinghausen SE, Puri RK, Rosenberg SA. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant IL-2 in mice. J Natl Cancer Inst 1988;80:177-88.
11. Bauer M, Reaman GH, Hank JA, Cairo MS, Anderson P, Blazar BR, et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Children's Cancer Group study. Cancer 1995;75:2959-65.
12. Munn DH, Cheung NKV. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 1987;47:6600-5.
13. Honsik CJ, Jung G, Reisfeld RA. LAK cells targeted by monoclonal antibody to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci U S A 1986;83:7893-7.
14. Shiloni E, Eisenthal A, Sachs D, Rosenberg SA. Antibodydependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J Immunol 1987;138:1992-8.
15. Hank JA, Robinson RR, Surfus J, Mueller BM. Reisfeld RA, Cheung NK, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990;50:5234-9.
16. Harel W, Shau H, Hadley CG, Morgan AC Jr., Reisfeld RA, Cheresh DA, et al. Increased lysis of melanoma by in vivoelicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. Cancer Res 1990;50:6311-5.
17. Bernstein N, Starnes CO, Levy R. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 1988;140:2835-9.
18. Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, et al. Combined therapy of mice bearing a lymphokine activated killer resistant tumor with recombinant IL-2 and antitumor monoclonal antibody capable of inducing antibody dependent cellular cytotoxicity. Cancer Res 1988;48:1173-9.
19. Schultz KR, Klarnet JP, Peace DJ, Cheever JA, Badger CC, Bernstein ID, et al. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells. Cancer Res 1990;50:5421-5.
20. Reisfeld RA. Antigen repertoire of human melanoma. Prog Clin Biol Res 1988;256:343-60.
21. Mujoo K, Cheresh D, Yang HM, Reisfeld RA. Disialoganglioside GD2 in human neuroblastoma: target antigen for monoclonal antibody mediated cytolysis and suppression of tumor growth. Cancer Res 1986;47:1098-104.
22. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, et al. Phase I trial of the murine monoclonal antiGD2 antibody 14 G2a in metastatic melanoma. Cancer Res 1992;52:4342-7.
23. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, et al. Phase I trial of murine monoclonal antibody 14.G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184-93.
24. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992;35:199-204.
25. Sondel PM. Immune mediated tumor destruction: challenges for the 1990s. In: Goldstein AL, Garaci E. Combination therapies. New York: Plenum Press, 1992;189-95.
26. Grabstein KH, Urdal DL, Tushinski RJ, Mochizuke DY, Price VL, Cantrell MA, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1996;232:506-8.
27. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK. Recombinant human granulocyte/macrophage colonystimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 1989;73:643-6.
28. Singh SM, Sone S, Inamura N, Ogura T. Up-regulation by granulocyte-macrophage colony-stimulating factor (GMCSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes. Int J Cancer 1989;44:170-6.
29. Masucci G, Ragnhammar P, Wersall P, Mellstedt H. Granulocyte-monocyte colony-stimulating factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother 1990;31:231-5.
30. Masucci G, Wersall P, Ragnhammar P, Mellstedt H. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibodydependent cellular cytotoxicity. Cancer Immunol Immunother 1989;29:288-92.
31. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer 1991;53:144-9.
32. Santoli D, Clark SC, Dreider BL, Maslin PA, Rovera G. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol 1988;142:519-26.
33. Oken MM, Creech RH, Tormey DC, Davis TE. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
34. Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, et al. Repetitive weekly cycles of recombinant human IL-2: response of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988;80:60-4.
35. Moss TJ, Seeger RC, Kindler-Rohrborn A, Marangos PJ, Rajewsky MF, Reynolds CP. Immunohistologic detection and phenotyping of neuroblastoma cells in bone marrow using cytoplasmic neuron specific enolase and cell surface antigens. Adv Neuroblastoma Res 1985;175:367-78.
36. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-26.
37. Cobbold SP, Rebello RP, Davies HP, Friend PJ, Clark MR. A simple method for measuring patient-antiglobulin responses against isotypic or idiotypic determinants. J Immunol Methods 1990;127:19-24.
38. Hank JA, Surfus J, Can J, Chew TL, Hong R, Tans K, et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994;15:29-37.
39. Albertini MR, Can J, Jaeger P, Hank JA, Storer B, Schell K, et al. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother 1996;19:278-95.
40. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, et al. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res 1989;49:2857-61.
41. Schiller J, Hank J, Khorsand M, Storer B, Borchert A, HusebyMoore K, et al. Clinical and immunological effects of GMCSF when administered with IL-2: a Phase IB study. Clin Cancer Res 1996;2:319-30.
42. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody dependent cytotoxicity with chimeric anti-GD2 antibody. J Immunol 1990;144:1282-6.
43. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31A:261-7.
44. Yu AL, Uttenreuther MM, Kamps A, Batova A, Reisfeld RA. Combined use of a human-mouse chimeric anti-GD2 (ch 14.18) in the treatment of refractory neuroblastoma [abstract]. Antibody Immunoconjugates Radiopharm 1995;8:12.
45. Becker JC, Pancook JD, Gillies SD, Mendelsohn J. Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A 1996;93:2702-7.
46. Sabzevari M, Gillies SD, Mueller BM, Pancook JDL, Reisfeld PA. A recombinant antibody-IL-2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A 1994;91:9626-30.
47. Hank JA, Surfus JE, Can J, Jaeger P, Gillies SD, Reisfeld RA, et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res 1996;2:1951-9.